Kyung Kim Selected Research

Kyung Kim Research Topics

Disease

18	Neoplasms (Cancer) 04/2020 - 07/2013
10	Stomach Neoplasms (Stomach Cancer) 01/2021 - 12/2017
3	Colonic Neoplasms (Colon Cancer) 01/2018 - 01/2017
2	Melanoma (Melanoma, Malignant) 08/2019 - 12/2016
2	Pancreatic Neoplasms (Pancreatic Cancer) 11/2018 - 01/2018
2	Colorectal Neoplasms (Colorectal Cancer) 01/2018 - 01/2017
2	Stroke (Strokes) 03/2014 - 01/2011
1	Erectile Dysfunction 10/2022
1	Adenocarcinoma 01/2020
1	Disease Progression 01/2020
1	Ototoxicity 11/2019
1	Reperfusion Injury 11/2018
1	Carcinoma (Carcinomatosis) 07/2018
1	Neoplasm Metastasis (Metastasis) 01/2018
1	Microsatellite Instability 01/2018
1	Hepatocellular Carcinoma (Hepatoma) 11/2017
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017
1	Inflammation (Inflammations) 05/2014
1	Uterine Neoplasms (Uterine Cancer) 07/2013

Drug/Important Bio-Agent (IBA)

4	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2017
2	LigandsIBA 04/2020 - 01/2018
2	pembrolizumabIBA 04/2020 - 01/2018
2	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 01/2020 - 10/2019
2	Sorafenib (BAY 43-9006)FDA Link 01/2018 - 01/2017
2	regorafenibIBA 11/2017 - 01/2017
1	Therapeutic UsesIBA 10/2022
1	Conditioned Culture MediaIBA 10/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2021
1	RamucirumabIBA 01/2021
1	Death Domain ReceptorsIBA 04/2020
1	PlatinumIBA 04/2020
1	Simvastatin (Zocor)FDA LinkGeneric 03/2020
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2020
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Cell-Free Nucleic AcidsIBA 01/2020
1	monoclonal antibody YYB-101IBA 01/2020
1	AminoglycosidesIBA 11/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2019
1	triptolideIBA 11/2018
1	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 07/2018
1	B7-H1 AntigenIBA 01/2018
1	Phosphotransferases (Kinase)IBA 01/2018
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2018
1	vandetanib (ZD6474)IBA 01/2018
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2017
1	AZD 6244IBA 12/2017
1	Proteins (Proteins, Gene)FDA Link 12/2017
1	c-Mer Tyrosine KinaseIBA 12/2017
1	RXDX-106IBA 12/2017
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2017
1	Messenger RNA (mRNA)IBA 01/2017
1	fms-Like Tyrosine Kinase 3IBA 01/2017
1	capivasertibIBA 01/2017
1	Circulating Tumor DNAIBA 01/2017
1	Cetuximab (Erbitux)FDA Link 01/2017
1	Everolimus FDA Link 01/2017
1	VemurafenibIBA 12/2016
1	dabrafenibIBA 12/2016
1	ElementsIBA 05/2014
1	Histones (Histone)IBA 05/2014
1	EnzymesIBA 05/2014

Therapy/Procedure

10	Therapeutics 01/2021 - 01/2017
2	Drug Therapy (Chemotherapy) 04/2020 - 01/2017
2	Activities of Daily Living (ADL) 03/2014 - 01/2011
1	Immunotherapy 08/2019
1	Nephroureterectomy 07/2018
1	Cystectomy 07/2018
1	Precision Medicine 01/2018
1	Adjuvant Chemoradiotherapy 09/2017
1	Length of Stay 07/2013
1	Lymph Node Excision (Lymph Node Dissection) 07/2013
1	Hysterectomy 07/2013